{"id":708671,"date":"2026-08-17T08:07:03","date_gmt":"2026-08-17T08:07:03","guid":{"rendered":"https:\/\/microscopemedia.com\/?p=708671"},"modified":"2026-08-17T08:07:03","modified_gmt":"2026-08-17T08:07:03","slug":"astrazeneca-abandoneaza-un-studiu-de-faza-iii-pentru-cancer-pulmonar-ce-s-a-intamplat-cu-medicamentul-testat","status":"publish","type":"post","link":"https:\/\/microscopemedia.com\/?p=708671","title":{"rendered":"AstraZeneca abandoneaz\u0103 un studiu de faz\u0103 III pentru cancer pulmonar. Ce s-a \u00eent\u00e2mplat cu medicamentul testat"},"content":{"rendered":"
\n
<\/div>\n<\/p><\/div>\n

Decizia reprezint\u0103 al doilea recul important \u00eenregistrat de companie \u00een cercetarea clinic\u0103 \u00een pu\u021bin peste o lun\u0103, relateaz\u0103 publica\u021bia The Independent<\/a>.<\/p>\n

Volrustomig nu a oferit beneficiile a\u0219teptate<\/h2>\n

AstraZeneca a anun\u021bat luni c\u0103 studiul \u00een care volrustomig era administrat \u00eempreun\u0103 cu chimioterapia va fi \u00eentrerupt. Datele disponibile au indicat c\u0103 aceast\u0103 combina\u021bie este pu\u021bin probabil s\u0103 \u00eembun\u0103t\u0103\u021beasc\u0103 supravie\u021buirea pacien\u021bilor cu cancer pulmonar \u00een compara\u021bie cu tratamentele existente.<\/p>\n

Hot\u0103r\u00e2rea a venit \u00een urma recomand\u0103rii unui comitet independent de monitorizare a datelor, care a analizat rezultatele \u00een cadrul unei evalu\u0103ri planificate a studiului.<\/p>\n

Susan Galbraith, vicepre\u0219edinte executiv al AstraZeneca, a declarat c\u0103 rezultatul este dezam\u0103gitor, dar c\u0103 grupul inten\u021bioneaz\u0103 s\u0103 foloseasc\u0103 informa\u021biile ob\u021binute pentru dezvoltarea viitoarelor terapii destinate pacien\u021bilor cu cancer pulmonar.<\/p>\n

Compania nu renun\u021b\u0103 \u00eens\u0103 complet la volrustomig. Medicamentul va continua s\u0103 fie evaluat \u00een studii care vizeaz\u0103 alte forme de cancer, printre care cancerul de col uterin, carcinomul scuamos al capului \u0219i g\u00e2tului \u0219i mezoteliomul.<\/p>\n

Al doilea recul pentru AstraZeneca \u00een pu\u021bin peste o lun\u0103<\/h2>\n

Decizia vine dup\u0103 ce, \u00een iulie, AstraZeneca a oprit un alt studiu clinic, de aceast\u0103 dat\u0103 pentru Wainua, un medicament investigat pentru o afec\u021biune cardiac\u0103. Anun\u021bul respectiv a provocat atunci o reac\u021bie puternic\u0103 pe burs\u0103 \u0219i a redus cu miliarde valoarea de pia\u021b\u0103 a companiei.<\/p>\n

Ve\u0219tile de luni nu au fost \u00eens\u0103 exclusiv negative pentru portofoliul oncologic al grupului. AstraZeneca a anun\u021bat rezultate favorabile pentru Enhertu \u00een cazul pacien\u021bilor cu cancer pulmonar f\u0103r\u0103 celule mici.<\/p>\n

Potrivit companiei, tratamentul a produs o \u00eembun\u0103t\u0103\u021bire semnificativ\u0103 statistic \u0219i relevant\u0103 clinic a supravie\u021buirii f\u0103r\u0103 progresia bolii. Programul va avansa c\u0103tre un studiu de faz\u0103 III.<\/p>\n

Ac\u021biunile AstraZeneca au crescut<\/h2>\n

Investitorii au primit pozitiv ansamblul informa\u021biilor publicate de companie. Ac\u021biunile AstraZeneca au urcat cu aproximativ 2% \u00een tranzac\u021biile de luni diminea\u021b\u0103.<\/p>\n

Cancerul pulmonar r\u0103m\u00e2ne una dintre principalele provoc\u0103ri ale oncologiei, fiind responsabil, potrivit datelor citate de presa britanic\u0103, de aproape 23% dintre decesele provocate de cancer.<\/p>\n

Pentru pacien\u021bii din Rom\u00e2nia \u0219i din restul Europei, evolu\u021bia unor astfel de studii este relevant\u0103 \u00een perspectiva introducerii unor noi terapii oncologice, \u00eens\u0103 accesul efectiv la un medicament depinde ulterior de autorizarea acestuia \u0219i de mecanismele na\u021bionale de compensare.<\/p>\n","protected":false},"excerpt":{"rendered":"

Decizia reprezint\u0103 al doilea recul important \u00eenregistrat de companie \u00een cercetarea clinic\u0103 \u00een pu\u021bin peste o lun\u0103, relateaz\u0103 publica\u021bia The Independent. Volrustomig nu a oferit beneficiile a\u0219teptate AstraZeneca a anun\u021bat … Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":708672,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/posts\/708671"}],"collection":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=708671"}],"version-history":[{"count":0,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/posts\/708671\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=\/wp\/v2\/media\/708672"}],"wp:attachment":[{"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=708671"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=708671"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/microscopemedia.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=708671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}